Scarica l'app Stockscreener
2.7913
6.30%
0.1713
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
Dip Buying: Does Esperion Therapeutics Inc align with a passive investing strategy2026 Sector Moves & Free Reliable Trade Execution Plans - baoquankhu1.vn
Esperion acquires Enbumyst maker Corstasis - MSN
Esperion (ESPR) highlights inclusion of bempedoic acid in 2026 ACC/AHA dyslipidemia guidelines - MSN
Esperion to acquire Corstasis for $75M upfront payment - MSN
Esperion Therapeutics prices $75M public offering - MSN
Esperion shares rise 8% after revenue tops forecasts and acquisition announced - MSN
Esperion (ESPR) Highlights Inclusion of Bempedoic Acid in 2026 ACC/AHA Dyslipidemia Guidelines - Insider Monkey
ESPR SEC FilingsEsperion Therape 10-K, 10-Q, 8-K Forms - Stock Titan
ESPR Stock Price, Quote & Chart | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down - MSN
Insider Selling: Esperion Therapeutics (NASDAQ:ESPR) Insider Sells $15,411.60 in Stock - MarketBeat
Esperion Therapeutics CFO Halladay sells $17k in stock By Investing.com - Investing.com India
Esperion Therapeutics CEO Koenig sells $69,546 in stock By Investing.com - Investing.com Canada
Esperion Therapeutics CFO Halladay sells $17k in stock - Investing.com
Esperion (NASDAQ: ESPR) CLO sells 5,708 shares to cover RSU tax bill - Stock Titan
Esperion Therapeutics (ESPR) CEO sells shares to pay RSU taxes - Stock Titan
Esperion (ESPR) CFO sells shares to cover taxes on vested RSUs - Stock Titan
Esperion outlines Vision 2040 with Corstasis acquisition and targets 2026 operating expenses up to $255M while expanding cardiometabolic portfolio - MSN
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Down 7.6%Here's What Happened - MarketBeat
Q1 EPS Estimate for Esperion Therapeutics Lowered by Analyst - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Stryker (SYK) and Esperion (ESPR) - The Globe and Mail
ESPR (NASDAQ: ESPR) affiliate files to sell 6,424 vested shares after vesting - Stock Titan
ESPR (NASDAQ: ESPR) Form 144 files planned sale of 5,708 shares - Stock Titan
Sheldon Koenig to sell 25,578 ESPR shares (NASDAQ: ESPR) under Form 144 - Stock Titan
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session - Bitget
Esperion to Present Two New Analyses From CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session - 富途牛牛
CLEAR Outcomes trial findings to be presented by Esperion Therapeutics at major cardiology event - Traders Union
Bempedoic acid data spotlight statin-intolerant, autoimmune patients - Stock Titan
BofA reiterates Esperion Therapeutics stock Underperform rating By Investing.com - Investing.com Canada
Esperion Therapeutics (ESPR) CFO receives major equity grants - Stock Titan
Esperion (ESPR) CLO receives new stock and option grants - Stock Titan
[Form 4] Esperion Therapeutics, Inc. In... - Stock Titan
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Up 7.8% Following Analyst Upgrade - MarketBeat
2026 cholesterol guideline backs bempedoic acid for statin-intolerant patients - Stock Titan
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia - Sahm
Operating cash flow per share of Esperion Therapeutics, Inc. – DUS:0ET - TradingView
Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference - MarketBeat
FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday - Sahm
Integral Health Asset Management LLC Purchases New Stake in Esperion Therapeutics, Inc. $ESPR - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Esperion Therapeutics soars amid vague takeover speculation - MSN
Esperion Therapeutics (NASDAQ:ESPR) Price Target Raised to $5.00 - MarketBeat
Citizens raises Esperion Therapeutics price target on drug growth By Investing.com - Investing.com Canada
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Esperion Therapeutics (ESPR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Equities Analysts Issue Forecasts for ESPR Q1 Earnings - MarketBeat
Esperion Stock Pre-Market (-0.1%): EPS Miss Mutes Revenue Beat & Acquisition News - Trefis
ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down - TradingView
Esperion at Citizens Life Sciences: Strategic Growth and Acquisition - Investing.com
What is HC Wainwright's Estimate for ESPR Q4 Earnings? - MarketBeat
Esperion Therapeutics (ESPR) Turns Q4 Profit As Bears Question Trailing Losses And Balance Sheet - Sahm
Esperion Therapeutics Q4 2025 earnings preview - MSN
2.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):